HAEMONETICS CORP — Director's Dealing 2013

Jul 26, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-07-24

Reporting Person: GELBMAN RONALD G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-07-24	Common Stock	A	1649.0	$0.0	Acquired	39173	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-07-24	Non-Qualified Stock Option (right to buy)	$45.45	A	6573.0	Acquired	2023-07-24	Common Stock (6573)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$13.0525	2014-05-05	Common Stock (12000)	12000	Direct
Non-Qualified Stock Option (right to buy)	$24.96	2014-08-01	Common Stock (9184)	9184	Direct
Non-Qualified Stock Option (right to buy)	$27.24	2017-07-29	Common Stock (8580)	8580	Direct
Non-Qualified Stock Option (right to buy)	$29.23	2015-07-31	Common Stock (11328)	11328	Direct
Non-Qualified Stock Option (right to buy)	$29.72	2016-07-30	Common Stock (11758)	11758	Direct
Non-Qualified Stock Option (right to buy)	$34.405	2018-07-21	Common Stock (7118)	7118	Direct
Non-Qualified Stock Option (right to buy)	$36.37	2019-07-27	Common Stock (8196)	8196	Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

F4: Grant to reporting person of right to buy shares of common stock exercisable immediately.